Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.01
Bid: 2.00
Ask: 2.15
Change: 0.055 (2.72%)
Spread: 0.15 (7.50%)
Open: 2.07
High: 2.07
Low: 1.91
Prev. Close: 2.02
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

Wed, 13th Apr 2022 11:06

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 59% at 9.00 pence, 12-month range 4.80p-10.90p. "Delighted" with positive data from the Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, as part of the new optimised international Phase 3 trial of Lupuzor in lupus patients. Study shows PK study has met the key endpoints requested by the FDA. "This positive PK data now clears the path for commencement of all clinical studies within the P140 platform. In addition to lupus, there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy," company notes.

----------

Shearwater Group PLC, up 25% at 136.42 pence, 12-month range 70.00p-230.00p. Subsidiary Brookcourt Solutions wins "significant" new contract win to the potential value of up to about GBP21.0 million with unnamed "leading telecommunications and media company". Initial, secured value of the contract, across an initial three year term, is GBP12.9 million, with the contract including an option to extend by a further two years for a total additional value of about GBP8.0 million.

----------

AIM - LOSERS

----------

Amur Minerals Corp, down 13% at 1.50 pence, 12-month range 1.00p-3.90p. Notes no individual or entity tied to company's AO Kun-Manie mine have been sanctioned in any round of EU, UK and US sanctions against Russia. Mine is in far east of Russia. Also notes flow of funds supporting AO Kun-Manie continue and company has now ensured sufficient cash reserves for the subsidiary covering budgeted costs through the first half 2022. Previously, AO Kun-Manie funds have been delivered to cover a 30 to 45 day period. Does say, however, company's lead legal consul representation in Moscow, Bryan Cave Leighton Paisner, is suspending operations within Russia. Company is reviewing options for lead Russian legal representation.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2016 08:47

ImmuPharma completes patient recruitment in Lupuzor trial

(ShareCast News) - Specialist drug discovery and development company ImmuPharma confirmed on Thursday that patient recruitment had successfully been completed, on target, within the its pivotal Phase III clinical trial of Lupuzor. The AIM-traded firm described Lupuzor as its lead programme for the p

Read more
16 Nov 2016 10:41

ImmuPharma Says Paper Detailing IPP-204106 Mechanism Published

Read more
14 Sep 2016 16:47

ImmuPharma makes positive progress in Lupuzor trials

(ShareCast News) - Specialist drug discovery and development company ImmuPharma updated the market on the progress of its Phase III clinical trial of Lupuzor - its lead programme for the potential breakthrough compound for Lupus - on Wednesday. The AIM-traded firm said it now had a total of 11 sites

Read more
14 Sep 2016 08:45

ImmuPharma Makes Progress With Lupuzor Phase III Trial

Read more
7 Jun 2016 06:59

ImmuPharma Begins Dosing Of European Patients In Lupuzor Trial

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
4 May 2016 09:17

ImmuPharma 2015 Loss Widens As It Focuses On Lupuzor Development

Read more
27 Apr 2016 15:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
9 Mar 2016 10:27

ImmuPharma Begins Patient Recruitment In Europe For Lupuzor Trial

Read more
15 Feb 2016 15:32

ImmuPharma doses first patients in the US

(ShareCast News) - ImmuPharma's clinical expansion into the US reached a significant point on Monday, with the first dosing of patients in its Phase III trial of the in-development lupus treatment Lupuzor. The AIM-traded drug discovery and development company confirmed in a statement that dosing had

Read more
15 Feb 2016 09:02

ImmuPharma Hopeful As US Patients Begin Dosing In Lupus Clinical Trial

Read more
5 Feb 2016 15:26

ImmuPharma to raise £7.5m for 'blockbuster' drug

(ShareCast News) - The 'blockbuster' potential of a drug in development saw ImmuPharma proposing a £7.5m fund raise on Friday. The AIM-traded specialist drug discovery and development company said the deal included a proposed conditional non-preemptive placing of no less than 11,824,877 Placing Shar

Read more
5 Feb 2016 10:32

WINNERS & LOSERS SUMMARY: Just Eat Leaps As It Gobbles Up Takeaways

Read more
5 Feb 2016 08:34

ImmuPharma Looks To Raise Minimum GBP7.5 Million In Equity (ALLISS)

Read more
7 Dec 2015 09:36

ImmuPharma Says US Sites Open For Lupuzor Phase III Trial Recruitment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.